In Brief
This article was originally published in The Tan Sheet
Executive Summary
Perrigo launches Aleve generic
You may also be interested in...
The Future Of OTCs: Self-Selection Meets Diagnostics, Genetic Personalization
The next generation of consumer health products, including Rx-to-OTC switch opportunities, may work in concert with cutting-edge diagnostic tools and elements of personalized medicine, says Andrew Fish.
Perrigo Banks On Product Launches, OTC Switches For "Significant Growth"
Perrigo is "poised for some significant growth" with $180 million in new product sales expected in the firm's current fiscal year, according to President and CEO Joseph Papa.
New Aleve formulation
Liquid Gels target active consumers ages 25 to 49 who suffer from back and joint pain, according to Bayer HealthCare. Available now in food, drug and mass retail outlets, Liquid Gels combine the all-day pain relieving power of Aleve (naproxen sodium) with "liquid-fast" speed and convenient dosing, according to the company. "Just two Aleve Liquid Gels can provide this all-day relief, where it would take four or even eight pills with other brands," the firm claims. The gels are sold in 20-, 40-, 80- and 160-count sizes, with suggested retail prices starting at $5.49...